Metal detectorist discovers unique golden artefact from Roman-era Germany: 'I could hardly believe it‘
The padlock, measuring just over a centimetre in size, was found in the northwestern region of Westphalia.
"The golden miniature box lock is completely unique in Europe," archaeologist Michael Rind from the Westphalia-Lippe Regional Association said.
Researchers found the artefact was a miniature version of locks used across Rome in the third and fourth centuries, hinting at trade between the empire and northern Germany during this time.
"I could hardly believe it when I held the find in my hand because such Roman locks are usually much larger and are made of iron or bronze parts,' the metal detectorist, Constantin Fried, said.
The lock's remains included only its cylindrical component, but in ancient times it likely had a key and a chain as well.
"Someone had obviously poked around in the lock at the time, probably to break it open or remove a blockage," Mr Fried said.
Initial restoration work revealed that the central cylinder was made of iron.
More detailed CT scans, utilising neutrons instead of the conventional X rays, found the lock's inner mechanism included a spring, bolt, baseplate, guide rail, and a pin.
The padlock could have been used to protect jewellery boxes or chests, similar to their modern counterparts, researchers said.
They were unsure, however, as to why such an intricate lock was made and what it was used to enclose by its German owners.
Researchers made a larger replica of the lock in brass and steel to better understand its mechanism. It suggested a 'high level of craftsmanship' of Roman blacksmith and metalworkers, according to LWL cultural director Barbara Rüschoff-Parzinger.
Researchers also concluded that the Westphalia region interacted with Rome during that time. "Was it a one-off or have similar precious miniatures simply not been found before? We will continue to work on these and other questions,' Mr Rind said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 days ago
- CNBC
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on different paths. Both Moderna and BioNTech helped pioneer mRNA, or messenger RNA, technology. Moderna staked its entire identity around mRNA, while BioNTech saw it as one piece of a broader portfolio focused on immunology and oncology. The pandemic gave both companies a chance to prove mRNA's promise of using the body's own immune system to protect against viruses or treat diseases. Covid vaccines have generated roughly $45 billion in sales for each company, earning them each about $20 billion since their rollout in late 2020. But despite parallel booms after the pandemic, the vaccine makers have since taken their businesses in different directions — and Wall Street has noticed. The two companies have spent their Covid vaccine windfall differently: Moderna doubled down on its mRNA pipeline, while BioNTech used the money to do deals and diversify, including into one of the hottest emerging areas of cancer drugs. Today, Moderna has about $8.4 billion in cash; the German-based BioNTech has €15.9 billion (or $18.2 billion). The divergence of the two companies is even more stark in their stock performance. Over the past year, Moderna shares have slid about 72%; BioNTech shares have gained nearly 29%. "Just their name was made based off the pandemic and the vaccines that they very quickly brought to people around the world to help get us through that period of time," said Evercore ISI analyst Cory Kasimov. "But the approach they're taking now and the outlook for these two companies is distinctly different at this point." Investors will get a fresh look at both companies' performance as they post quarterly results in the coming days. Moderna is set to report Friday morning, followed by BioNTech on Monday morning. Moderna used its Covid cash to build out its mRNA portfolio, particularly vaccines. It invested in shots for flu, RSV and lesser-known viruses like cytomegalovirus and norovirus. "From our perspective, the pandemic really showed that the science of what we're doing worked, and the natural sort of response to that was to continue down that path and do more," said Moderna President Stephen Hoge. Funding such a large pipeline wasn't cheap. The company has started slashing expenses as sales of its Covid vaccine slide and its RSV vaccine struggles to find a foothold. But the clock is running, said Leerink analyst Mani Foroohar. "We're moving into a time where being a vaccine company is going to be more expensive, tedious and onerous," Foroohar said, citing changes at the Food and Drug Administration under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., who has expressed skepticism about vaccines. Foroohar in 2022 pointed out what he saw as a Shakespearean tragic flaw in Moderna's business model. That shortcoming, in his view, is that Moderna scaled its pipeline assuming mRNA technology would be the tool for all problems instead of a solution for some problems. Hoge said Moderna's "really good at making mRNA medicines" and decided to focus on doing that. "The reality is that we think over the last 10 years, that focus has actually made us successful, and in the pandemic, it certainly had a big impact and obviously was something that sets us up for the more diverse pipeline we have right now," Hoge said. "So we recognize that we may be going through some cycles, but we're pretty confident in the long-term trajectory we're on, and we're looking forward over the years ahead to showing with all these additional medicines what we're really capable of." Meanwhile, BioNTech decided to use the proceeds from its Covid vaccine to diversify. Out of the limelight as partner Pfizer took the lead on selling the companies' shot, BioNTech expanded into promising new cancer technologies. Most importantly, it acquired a bispecific antibody targeting the proteins PD-L1 and VEG-F. That technology promises to build on – and possibly best – the success that Merck has found with Keytruda, a cancer drug with nearly $30 billion in sales last year alone. That thesis still needs to be proven in large, global clinical trials, but BioNTech is already seeing that deal pay off. Bristol Myers Squibb in June announced it would pay up to $11 billion to partner with BioNTech to codevelop the experimental drug, which BioNTech acquired for a fraction of that. BioNTech in 2023 initially paid Biotheus $55 million up front to license the drug outside China before acquiring the company outright earlier this year for up to $1 billion. "[BioNTech] found an asset, they developed it, and then they got a pharma partner, it's like a dream," said BMO analyst Evan David Seigerman. "So they're really strategic in that, and I think they're adding a lot of diversification, which makes the story a lot less risky if you're just focused on mRNA, vaccines and Covid, and that's super risky, in my view." At the same time, hopes are high that BioNTech's bispecific antibody drug will work, meaning any disappointment ahead could hurt the stock. Investors are watching forthcoming Phase 3 trial results from Summit Therapeutics, which is testing a similar drug for lung cancer. Those data could help — or hurt — BioNTech's stock while it awaits data from its own studies, which could take until 2028. For Moderna, investors want to see if sales of its Covid and RSV vaccines can rebound. The company is also seeking FDA approval for an mRNA flu shot. But at this point, the most intense focus is on Moderna's Phase 3 trial for a personalized cancer treatment for melanoma, said RBC Capital Markets analyst Luca Issi. Moderna may be able to share the first interim data as soon as next year, Hoge said, though the company can't promise an exact date since it's an event-driven study. That means enough people in the trial need to relapse before Moderna can analyze whether its treatment kept cancer from returning longer. If the treatment succeeds, it could launch in 2027 or 2028, Hoge said. That leaves Moderna largely dependent on its vaccines until then. An ongoing patent dispute over Moderna's Covid-19 shot could also eat into the company's cash, analysts say, adding they expect the legal proceedings to play out next year. Time will tell whether the divergent strategies win over Wall Street long term.
USA Today
3 days ago
- USA Today
Video shows sea lions diving off cliff after massive earthquake strikes Russia's far east
A powerful earthquake that struck Russia's Kamchatka Peninsula on July 30 prompted a group of sea lions to dive into nearby waters in search of safety, footage of the ordeal shows. The video taken by a tourist on a nature day trip shows at least 30 sea lions jumping off cliffs and into the waves for safety as an 8.8-magnitude earthquake struck the island of Antsiferov. The earthquake also prompted tsunami alerts along America's West Coast, from Alaska to Hawaii, with no immediate damage reported. Meanwhile, authorities in Ecuador's Galapagos Islands have ordered a precautionary evacuation for residents living in vulnerable areas along the Pacific coast, according to Reuters. More on sea lions on the island The island affected by the earthquake is home to Steller sea lions, the largest members of the family Otariidae, which includes "eared seals," according to the National Oceanic and Atmospheric Administration Fisheries. The species was named after German surgeon and naturalist Georg Wilhelm Steller, who described it in 1742, according to NOAA Fisheries. The seals can be found mainly along the North Pacific Ocean rim from northern Hokkaido, Japan, to the Kuril Islands and Sea of Okhotsk. They can also be found in the Aleutian Islands and Bering Sea, the southern coast of Alaska and south to central California. Adult males tend to be much larger than females, the agency said. Adult males can be up to 11 feet long and can weigh up to 2,500 pounds, while adult females are 7.5 to 9.5 feet long and weigh up to 800 pounds. They primarily feed at night and consume over 100 species of fish, including mackerel, walleye pollock, salmon, Pacific cod, flounder and others. They can forage both nearshore and offshore, and can travel long distances within a single season. Disturbances and how they impact sea lions The creatures need 'undisturbed land habitat to rest, molt, socialize, mate, give birth, and nurse small pups during the breeding season,' NOAA Fisheries said. The agency also said Steller sea lions have been disturbed in the past by powerboats, kayaks, paddleboards and other watercraft, as well as approaching aircraft.. 'Disturbance to Steller sea lions on terrestrial haulout sites can lead to individuals fleeing toward the water, causing mass stampedes during which pups and juveniles may be injured or killed when crushed by adults,' the agency said. 'Disturbance can also cause sea lions to flee from the tops of steep rocks or cliff faces, also causing injury or death.' Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@
CNN
3 days ago
- CNN
Roman-era ‘church' in Spain may have been a synagogue
Archaeologists working at a site in Spain say they have uncovered evidence of what may have been a synagogue used by a hitherto unknown Jewish community. While excavating the site, previously believed to be a church dating from the 4th century, experts found materials and architectural evidence that led them to hypothesize that the building was, in fact, a synagogue, according to a study published earlier this month. Artifacts such as fragments of oil lamps and a piece of roof tile decorated with menorahs were found during excavations in Cástulo, a former Roman settlement in southern Spain, whereas no materials that have a clear association with the Christian faith have been found at the site. In contrast, archaeologists have found evidence of Christian worship at another site in the town, study author Bautista Ceprián, an archaeologist with the Cástulo Sefarad Primera Luz project, told CNN on Wednesday. The building also has a squarer shape than Christian churches, which tend to be more rectangular, and archaeologists found what could have been a hole for supporting a large menorah, as well as the foundations of a central raised platform, or bimah, which is common in synagogues but not in churches, he added. In addition, no tombs were discovered at the building, which was built near an abandoned Roman temple — something that would have been feared by Christian residents because of its association with paganism, he added. 'It's a hidden, discreet and isolated spot that would not have been visited often by the Christian majority,' Ceprián said. Taken together, this evidence points to the existence of a previously unknown Jewish community in the town, the study authors argue. 'The reinterpretation of the building from a church to possibly a synagogue followed a process of logical reasoning based on the historical and archaeological data in our possession,' Ceprián said. Nonetheless, the lack of written records of a Jewish community in Cástulo leaves room for some doubt, as the study authors acknowledged. Speculating about the daily life of the community would be 'a very dangerous exercise,' Ceprián said, but they would have lived alongside their fellow Roman citizens in the town. The population is then thought to have disappeared, as it is not named in the anti-Jewish law enacted by Visigoth King Sisebut, who ruled what is now Spain from 612 to 621, whereas the Jewish communities in other nearby towns are specifically named. As for what would have happened to them, 'it is difficult to know,' Ceprián said. One possible explanation is that the Christian clergy feared the local population would convert to Judaism, given the 'close and friendly relations' between the two groups in the region at the time, he said. This concern drove Christian leaders, who were becoming increasingly influential in the Roman Empire, to foment fear of and opposition to Jewish communities, said Ceprián. This culminated in episodes starting around the end of the 4th century in which Jewish citizens were pressured to convert to Christianity, with those who refused 'amicably invited' to leave their hometowns, he said, adding that this kind of incident could have plausibly occurred in Cástulo sometime between the end of the 5th century and the beginning of the 7th century. Now the team will work to protect the site and excavations will continue, Ceprián said. They aim to allow the public to visit at some point in the future, he added. 'We can't rule out the possibility of finding more definitive evidence that allows us to update our hypothesis of a possible synagogue to an actual synagogue,' he said. Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
